Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. YMAB
YMAB logo

YMAB Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
541.07M
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
328.93M
EV/OCF(TTM)
--
P/S(TTM)
4.54
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform (PRIT) and bispecific antibodies generated using the Y-BiClone platform. Its segments include DANYELZA and RIT. The Company’s advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), the first food and drug administration (FDA)-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody, or monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
Show More

Events Timeline

(ET)
2025-08-08
06:43:17
Y-mAbs Therapeutics reports Q2 EPS (7c), consensus (25c)
select

News

Globenewswire
7.0
2025-08-26Globenewswire
SHAREHOLDER INQUIRY: Halper Sadeh LLC Probes VRNT, DAY, WOW, YMAB for Shareholder Interests
  • Investigation Announcement: Halper Sadeh LLC is investigating potential violations of federal securities laws and breaches of fiduciary duties related to the sales of several companies, including Verint Systems Inc., Dayforce, WideOpenWest, and Y-mAbs Therapeutics.

  • Sales Details: The firms involved are being sold for specific cash amounts per share: Verint at $20.50, Dayforce at $70.00, WideOpenWest at $5.20, and Y-mAbs at $8.60.

  • Legal Rights for Shareholders: Shareholders of the mentioned companies are encouraged to learn about their legal rights and options regarding these transactions, with Halper Sadeh LLC offering free consultations.

  • Contingent Fee Basis: The law firm operates on a contingent fee basis, meaning shareholders will not incur out-of-pocket expenses for legal fees or costs related to the investigation.

Globenewswire
7.0
2025-08-26Globenewswire
BRODSKY & SMITH INVESTOR ALERT: Updates on Investigations Involving Verint Systems Inc. (Nasdaq – VRNT), Dayforce, Inc. (NYSE – DAY), WideOpenWest, Inc. (NYSE – WOW), and Y-mAbs Therapeutics, Inc. (Nasdaq – YMAB)
  • Investigation Announcements: Brodsky & Smith is reminding investors of ongoing investigations regarding potential breaches of fiduciary duties by company boards in recent merger agreements.

  • Dayforce, Inc. Acquisition: Dayforce will be acquired by Thoma Bravo for $70.00 per share, but the investigation questions if this offer reflects fair value compared to its 52-week high of $82.69.

  • WideOpenWest, Inc. Deal: WOW is set to be acquired for $5.20 per share, with concerns raised about whether the board adequately ensured a fair process and valuation for shareholders.

  • Verint Systems and Y-mAbs Transactions: Verint will be acquired for $20.50 per share (below its 52-week high of $34.80), while Y-mAbs will be sold for $8.60 per share, both facing scrutiny over the fairness of their respective deals.

Globenewswire
7.0
2025-08-21Globenewswire
SHAREHOLDER INQUIRY: Halper Sadeh LLC Probes DAY, WOW, YMAB, STAA for Shareholder Interests
  • Investigation Announcement: Halper Sadeh LLC is investigating potential violations of federal securities laws and breaches of fiduciary duties related to several companies' sales.

  • Companies Under Review: The firms being investigated include Dayforce, WideOpenWest, Y-mAbs Therapeutics, and STAAR Surgical, each with specific sale prices per share outlined.

  • Shareholder Rights: Shareholders of the mentioned companies are encouraged to learn about their rights and options regarding the proposed transactions.

  • Legal Representation Offer: Halper Sadeh LLC offers legal representation on a contingent fee basis, meaning no upfront costs for shareholders seeking assistance.

Globenewswire
7.0
2025-08-21Globenewswire
BRODSKY & SMITH INVESTOR ALERT: Updates on Investigations Involving Dayforce, Inc. (NYSE- DAY), WideOpenWest, Inc. (NYSE - WOW), STAAR Surgical Company (Nasdaq – STAA), and Y-mAbs Therapeutics, Inc. (Nasdaq – YMAB)
  • Investigation Announcements: Brodsky & Smith is reminding investors about ongoing investigations related to several companies regarding potential breaches of fiduciary duties by their boards during acquisition processes.

  • Dayforce, Inc. Acquisition: Dayforce is set to be acquired by Thoma Bravo for $70.00 per share, but the investigation questions whether this offer reflects fair value given the company's 52-week high of $82.69.

  • WideOpenWest, Inc. Deal: WOW will be acquired for $5.20 per share by DigitalBridge Investments and Crestview Partners, with concerns raised about the fairness of this deal for shareholders.

  • Other Company Investigations: Similar investigations are underway for STAAR Surgical Company and Y-mAbs Therapeutics, both facing scrutiny over whether their respective acquisition offers provide fair value to shareholders.

Globenewswire
7.0
2025-08-20Globenewswire
SHAREHOLDER INQUIRY: Halper Sadeh LLC Probes VBTX, TASK, YMAB for Shareholder Interests
  • Investigation Announcement: Halper Sadeh LLC is investigating potential violations of federal securities laws and breaches of fiduciary duties related to the sales of Veritex Holdings, TaskUs, and Y-mAbs Therapeutics.

  • Veritex Holdings Sale: Veritex Holdings is set to be sold to Huntington Bancshares, with shareholders receiving 1.95 shares of Huntington for each share of Veritex.

  • TaskUs Sale Details: TaskUs is being sold to Blackstone affiliates and its executives for $16.50 per share.

  • Legal Support for Shareholders: Halper Sadeh LLC offers legal assistance to affected shareholders at no upfront cost, aiming to secure increased compensation or additional disclosures regarding the transactions.

Globenewswire
7.0
2025-08-19Globenewswire
Investor Alert on Y-MABS Therapeutics: Kahn Swick & Foti, LLC, Led by Former Louisiana Attorney General, Examines Price and Process in Proposed Sale of Y-mAbs Therapeutics, Inc. - YMAB
  • Investigation Announcement: Former Louisiana Attorney General Charles C. Foti, Jr. and Kahn Swick & Foti, LLC are investigating the proposed sale of Y-mAbs Therapeutics, Inc. to SERB Pharmaceuticals.

  • Transaction Details: Shareholders of Y-mAbs are set to receive $8.60 in cash per share under the terms of the proposed transaction.

  • Concerns Raised: KSF is assessing whether the offered consideration adequately reflects the value of Y-mAbs and if the sales process was appropriate.

  • Contact Information: Interested parties can contact KSF for discussions regarding their legal rights related to the sale via email or phone, with urgency noted due to the tender offer structure of the transaction.

Wall Street analysts forecast YMAB stock price to rise
11 Analyst Rating
Wall Street analysts forecast YMAB stock price to rise
0 Buy
10 Hold
1 Sell
Hold
Current: 0.000
sliders
Low
3.00
Averages
7.98
High
8.60
Current: 0.000
sliders
Low
3.00
Averages
7.98
High
8.60
H.C. Wainwright
Robert Burns
Buy -> Neutral
downgrade
$11
AI Analysis
2025-08-06
Reason
H.C. Wainwright
Robert Burns
Price Target
$11
AI Analysis
2025-08-06
downgrade
Buy -> Neutral
Reason
H.C. Wainwright analyst Robert Burns downgraded Y-mAbs Therapeutics to Neutral from Buy with a price target of $8.60, down from $11, after the company entered into a merger agreement under which Serb will acquire Y-mAbs for $8.60 per share. The firm does not expect rival bidders to emerge.
Wedbush
Outperform -> Neutral
downgrade
2025-08-05
Reason
Wedbush
Price Target
2025-08-05
downgrade
Outperform -> Neutral
Reason
Wedbush downgraded Y-mAbs Therapeutics to Neutral from Outperform with an $8.60 price target after SERB Pharmaceuticals agreed to acquire Y-mAbs for $8.60 per share in cash.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for YMAB
Unlock Now

Valuation Metrics

The current forward P/E ratio for Y-mAbs Therapeutics Inc (YMAB.O) is -6.07, compared to its 5-year average forward P/E of -11.32. For a more detailed relative valuation and DCF analysis to assess Y-mAbs Therapeutics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-11.32
Current PE
-6.07
Overvalued PE
-3.71
Undervalued PE
-18.93

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-9.85
Current EV/EBITDA
-8.59
Overvalued EV/EBITDA
-2.11
Undervalued EV/EBITDA
-17.59

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
7.53
Current PS
2.37
Overvalued PS
14.41
Undervalued PS
0.65

Financials

AI Analysis
Annual
Quarterly

Whales Holding YMAB

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Y-mAbs Therapeutics Inc (YMAB) stock price today?

The current price of YMAB is 0 USD — it has increased 0

What is Y-mAbs Therapeutics Inc (YMAB)'s business?

Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform (PRIT) and bispecific antibodies generated using the Y-BiClone platform. Its segments include DANYELZA and RIT. The Company’s advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), the first food and drug administration (FDA)-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody, or monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.

What is the price predicton of YMAB Stock?

Wall Street analysts forecast YMAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for YMAB is7.98 USD with a low forecast of 3.00 USD and a high forecast of 8.60 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Y-mAbs Therapeutics Inc (YMAB)'s revenue for the last quarter?

Y-mAbs Therapeutics Inc revenue for the last quarter amounts to 19.52M USD, decreased -14.36

What is Y-mAbs Therapeutics Inc (YMAB)'s earnings per share (EPS) for the last quarter?

Y-mAbs Therapeutics Inc. EPS for the last quarter amounts to -0.07 USD, decreased -66.67

How many employees does Y-mAbs Therapeutics Inc (YMAB). have?

Y-mAbs Therapeutics Inc (YMAB) has 107 emplpoyees as of April 01 2026.

What is Y-mAbs Therapeutics Inc (YMAB) market cap?

Today YMAB has the market capitalization of 541.07M USD.